The Development of Therapeutic Vaccines to Treat HPV-mediated Cervical Cancers
Article Sidebar
Main Article Content
Abstract
This literature review investigates the development of therapeutic vaccines to treat HPV-mediated cervical cancers. Specifically, HPV-16 targeting vaccines are reviewed. Vaccines are grouped by type: vector-based, DNA-based, synthetic plasmids, and long peptide vaccines. The review is based on study endpoints, tolerability, safety, and efficacy. Commonalities seen throughout all studies were the use of E6 and E7 proteins as targets, IFNy response measures, and regression as a marker of efficacy. Each vaccination against HPV-16 mediated cervical cancer showed tolerability and safety. However, they did not all show adequate efficacy. The two DNA/RNA-based vaccinations that showed the most promising results were VB10.16 and VGX-3100. This indicates that further research is needed within this field.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All content in this journal is published under a Creative Commons Attribution Non-Commercial license. Content can be freely shared, distributed, modified, and reused, providing credit is given to the original author, and the work is not used in any commercial context.